Sequoia Financial Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,947 shares of the biopharmaceutical company’s stock after purchasing an additional 1,198 shares during the period. Sequoia Financial Advisors LLC’s holdings in Gilead Sciences were worth $2,239,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of GILD. TRUE Private Wealth Advisors bought a new position in shares of Gilead Sciences in the fourth quarter worth $25,000. Pin Oak Investment Advisors Inc. bought a new position in shares of Gilead Sciences in the fourth quarter worth $26,000. Baldwin Brothers Inc. MA increased its position in shares of Gilead Sciences by 63.3% in the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 136 shares during the period. IndexIQ Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Finally, TFO TDC LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth $29,000. Institutional investors own 77.34% of the company’s stock.
In related news, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Brett A. Pletcher sold 10,441 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $70.88, for a total value of $740,058.08. Following the completion of the transaction, the executive vice president now directly owns 25,085 shares in the company, valued at $1,778,024.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,585 shares of company stock worth $4,671,283. 0.13% of the stock is owned by insiders.
Shares of NASDAQ:GILD traded down $0.16 during midday trading on Friday, hitting $73.34. 6,157,451 shares of the stock were exchanged, compared to its average volume of 19,139,120. The stock has a market capitalization of $92.20 billion, a price-to-earnings ratio of 18.85, a P/E/G ratio of 3.14 and a beta of 0.72. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. The business’s 50-day moving average price is $77.78 and its 200 day moving average price is $70.16. Gilead Sciences, Inc. has a 12 month low of $60.89 and a 12 month high of $85.97.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.11. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.67 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.34 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.71%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s dividend payout ratio is currently 44.30%.
GILD has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Sunday, April 19th. Cowen reiterated a “buy” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Monday, April 13th. Royal Bank of Canada reiterated a “buy” rating and issued a $88.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 5th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 13th. Finally, Wolfe Research started coverage on Gilead Sciences in a research report on Tuesday, March 31st. They issued a “market perform” rating and a $65.00 target price on the stock. Seven investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have assigned a buy rating to the company. Gilead Sciences currently has an average rating of “Hold” and a consensus price target of $78.15.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.